Glimepiride

Drug Profile

Glimepiride

Alternative Names: Amarel; Amaril; Amaryl; HOE-490; Roname

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer Lacer; Sanofi; Shandong Zibo - Xinhua - Chemferm (JV)
  • Class Antihyperglycaemics; Small molecules; Sulfonylureas
  • Mechanism of Action Potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 31 Jan 2014 Sanofi completes the phase III RECOMMEND trial in Type-2 diabetes mellitus (combination therapy) in Algeria, Colombia, Egypt, Guatemala, India, Iran, Lebanon, Mexico, Russia, Saudi Arabia, South Africa, Tunisia, Turkey, Ukraine and the United Arab Emirates (NCT01459809)
  • 16 Feb 2012 Phase-III clinical trials in Type-2 diabetes mellitus (combination therapy) in Algeria, Colombia, Egypt, India, Iran, Lebanon, Mexico, Russia, Saudi Arabia, South Africa, Tunisia, Turkey, Ukraine and United Arab Emirates (Oral) after February 2012
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top